These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 19815667)
21. Silencing activity of 2'-O-methyl modified anti-MDR1 siRNAs with mismatches in the central part of the duplexes. Petrova NS; Meschaninova MI; Venyaminova AG; Zenkova MA; Vlassov VV; Chernolovskaya EL FEBS Lett; 2011 Jul; 585(14):2352-6. PubMed ID: 21704032 [TBL] [Abstract][Full Text] [Related]
22. Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism. Dykxhoorn DM; Schlehuber LD; London IM; Lieberman J Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5953-8. PubMed ID: 16585504 [TBL] [Abstract][Full Text] [Related]
23. DEQOR: a web-based tool for the design and quality control of siRNAs. Henschel A; Buchholz F; Habermann B Nucleic Acids Res; 2004 Jul; 32(Web Server issue):W113-20. PubMed ID: 15215362 [TBL] [Abstract][Full Text] [Related]
24. Predicting siRNA efficiency. Li W; Cha L Cell Mol Life Sci; 2007 Jul; 64(14):1785-92. PubMed ID: 17415516 [TBL] [Abstract][Full Text] [Related]
25. Allele-specific silencing by RNA interference. Hohjoh H Methods Mol Biol; 2010; 623():67-79. PubMed ID: 20217544 [TBL] [Abstract][Full Text] [Related]
26. siRNA function in RNAi: a chemical modification analysis. Chiu YL; Rana TM RNA; 2003 Sep; 9(9):1034-48. PubMed ID: 12923253 [TBL] [Abstract][Full Text] [Related]
27. siRNA has greatly elevated mismatch tolerance at 3'-UTR sites. Wei N; Zhang L; Huang H; Chen Y; Zheng J; Zhou X; Yi F; Du Q; Liang Z PLoS One; 2012; 7(11):e49309. PubMed ID: 23145149 [TBL] [Abstract][Full Text] [Related]
28. A novel siRNA validation system for functional screening and identification of effective RNAi probes in mammalian cells. Hung CF; Lu KC; Cheng TL; Wu RH; Huang LY; Teng CF; Chang WT Biochem Biophys Res Commun; 2006 Aug; 346(3):707-20. PubMed ID: 16793020 [TBL] [Abstract][Full Text] [Related]
29. Re-Engineering RNA Molecules into Therapeutic Agents. Egli M; Manoharan M Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917 [TBL] [Abstract][Full Text] [Related]
30. The potency of siRNA-mediated growth inhibition following silencing of essential genes is dependent on siRNA design and varies with target sequence. Patel R; T'wallant NC; Herbert MH; White D; Murison JG; Reid G Oligonucleotides; 2009 Dec; 19(4):317-28. PubMed ID: 19943803 [TBL] [Abstract][Full Text] [Related]
31. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Elbashir SM; Martinez J; Patkaniowska A; Lendeckel W; Tuschl T EMBO J; 2001 Dec; 20(23):6877-88. PubMed ID: 11726523 [TBL] [Abstract][Full Text] [Related]
32. Tailor-made RNAi knockdown against triplet repeat disease-causing alleles. Takahashi M; Watanabe S; Murata M; Furuya H; Kanazawa I; Wada K; Hohjoh H Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21731-6. PubMed ID: 21098280 [TBL] [Abstract][Full Text] [Related]
33. C911: A bench-level control for sequence specific siRNA off-target effects. Buehler E; Chen YC; Martin S PLoS One; 2012; 7(12):e51942. PubMed ID: 23251657 [TBL] [Abstract][Full Text] [Related]
34. siRNAs containing 2'-fluorinated Northern-methanocarbacyclic (2'-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2'-F-NMCÂ NTPs. Akabane-Nakata M; Erande ND; Kumar P; Degaonkar R; Gilbert JA; Qin J; Mendez M; Woods LB; Jiang Y; Janas MM; O'Flaherty DK; Zlatev I; Schlegel MK; Matsuda S; Egli M; Manoharan M Nucleic Acids Res; 2021 Mar; 49(5):2435-2449. PubMed ID: 33577685 [TBL] [Abstract][Full Text] [Related]
36. Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A. Mook OR; Baas F; de Wissel MB; Fluiter K Cancer Gene Ther; 2009 Jun; 16(6):532-8. PubMed ID: 19165236 [TBL] [Abstract][Full Text] [Related]
37. Picking a winner: new mechanistic insights into the design of effective siRNAs. Gong D; Ferrell JE Trends Biotechnol; 2004 Sep; 22(9):451-4. PubMed ID: 15331225 [TBL] [Abstract][Full Text] [Related]
38. The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. Saayman S; Barichievy S; Capovilla A; Morris KV; Arbuthnot P; Weinberg MS PLoS One; 2008 Jul; 3(7):e2602. PubMed ID: 18596982 [TBL] [Abstract][Full Text] [Related]
39. Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Chang CI; Yoo JW; Hong SW; Lee SE; Kang HS; Sun X; Rogoff HA; Ban C; Kim S; Li CJ; Lee DK Mol Ther; 2009 Apr; 17(4):725-32. PubMed ID: 19156133 [TBL] [Abstract][Full Text] [Related]
40. A rational study for identification of highly effective siRNAs against hepatitis B virus. Thongthae N; Payungporn S; Poovorawan Y; T-Thienprasert NP Exp Mol Pathol; 2014 Aug; 97(1):120-7. PubMed ID: 24953337 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]